Nivalis Therapeutics (NVLS) Reports Q3 Loss of $0.39/Share

Nivalis Therapeutics (NASDAQ: NVLS) reported Q3 EPS of ($0.39), versus ($7.68) reported last year.

For earnings history and earnings-related data on Nivalis Therapeutics (NVLS) click here.

You May Also Be Interested In

• PG&E downgraded by Wells Fargo, BMO as California wildfire reform falls short
• RBC Capital Resumes BorgWarner (BWA) at Outperform
• Citi raises Atlassian price target to $225, maintains Buy rating